ArticleAnnals of medicine2026
Construction and validation of an identification model for frailty in maintenance hemodialysis patients using multiple machine learning algorithms: a cross-sectional study of retrospectively collected data.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFrailty adversely affects survival and quality of life in patients undergoing maintenance hemodialysis (MHD). This study aimed to develop a clinical multimodal model to identify prevalent frailty in MHD patients.
methodsClinical data from 626 MHD patients across four tertiary hospitals were retrospectively collected, including demographics, clinical characteristics, laboratory indicators, and physical function assessments. Frailty was assessed using the FRAIL scale. Patients from Wuxi (
resultsFrailty prevalence was 48.6%. Six predictors were identified: age, grip strength, comorbidities, Charlson comorbidity index (CCI), albumin, and pro-B-type natriuretic peptide (pro-BNP). The extreme gradient boosting (XGBoost) achieved the best external validation performance (AUC=0.917, 95% CI: 0.867-0.967; accuracy=0.847; sensitivity=0.850; specificity=0.844), with good calibration and clinical net benefit. The shapley additive explanations (SHAP) identified pro-BNP as the most influential predictor and revealed nonlinear associations and clinically relevant thresholds.
conclusionThe interpretable XGBoost model effectively identified prevalent frailty in MHD patients, demonstrating strong discrimination, calibration, and clinical applicability, and may support systematic frailty screening and individualized assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.